{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:08:25Z","timestamp":1784855305174,"version":"3.55.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1093\/jac\/dkx033","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T12:09:21Z","timestamp":1487592561000},"page":"i48-i58","source":"Crossref","is-referenced-by-count":27,"title":["New pharmacological opportunities for the treatment of invasive mould diseases"],"prefix":"10.1093","volume":"72","author":[{"given":"Marie-Pierre","family":"Ledoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"key\n\t\t\t\t20170317082738_dkx033-B1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B2","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B5"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B6","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B7","author":"ESCMID\/ESDMI (European Society of Clinical Microbiology and Infectious Disease Fungal Infections Study Group","year":"2014"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B8","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis aspergillosis, and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume-title":"Haematologica","year":"2013"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B9","first-page":"2192","article-title":"Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis","volume":"4","year":"2008","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/11593760-000000000-00000","article-title":"Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients","volume":"31","year":"2011","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B11","first-page":"CD006343","article-title":"Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections","volume":"2","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"L Amph\/ABLC Collaborative Study Group","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B15","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10\u2009mg\/kg\/day) liposomal amphotericin B (LAmB) for the initial treatment of mucormycosis","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","year":"2013","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1634\/theoncologist.2010-0290","article-title":"Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles","volume":"16","year":"2011","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","article-title":"Voriconazole in clinical practice","volume":"24","year":"2012","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","year":"2005","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B20","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.2174\/13816128113199990342","article-title":"Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis","volume":"19","year":"2013","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B21","doi-asserted-by":"crossref","first-page":"i25","DOI":"10.1093\/jac\/dkq439","article-title":"Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease","volume":"66","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B26","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B27"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B30","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","year":"2013","journal-title":"Infect Drug Resist"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B31","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B33","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case\u2013control analysis","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B36","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: Pharmacokinetic and pharmacodynamic considerations","volume":"72","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B37","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study","volume":"45","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B39","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B40","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s10156-013-0594-9","article-title":"Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review","volume":"19","year":"2013","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B41","first-page":"589490","article-title":"Combination antifungal therapy in the treatment of Scedosporium apiospermum central nervous system infections","volume":"2013","year":"2013","journal-title":"Case Rep Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1399-3062.2007.00203.x","article-title":"Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient","volume":"9","year":"2007","journal-title":"Transplant Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365540600786564","article-title":"Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine","volume":"39","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-3062.2007.00240.x","article-title":"Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient","volume":"10","year":"2008","journal-title":"Transplant Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05007.x","article-title":"Toward more effective antifungal therapy: the prospects of combination therapy","volume":"126","year":"2004","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B46","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B47","first-page":"296","article-title":"In vivo synergy of amphotericin B plus posaconazole in murine aspergillosis","volume":"60","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B49","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1128\/AAC.00980-12","article-title":"In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B50","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1128\/AAC.00833-13","article-title":"Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/eri.13.29","article-title":"Combination antifungal therapy for invasive fungal infections in children and adults","volume":"11","year":"2013","journal-title":"Expert Rev anti Infect Ther"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1439-0507.2009.01808.x","article-title":"A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections","volume":"54","year":"2011","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.riam.2014.10.003","article-title":"Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment","volume":"32","year":"2015","journal-title":"Rev Iberoam Micol"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jinf.2005.01.006","article-title":"Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections","volume":"52","year":"2006","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B55","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/myc.12161","article-title":"Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study","volume":"57","year":"2014","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","year":"2006","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B58","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what and how?","volume":"54","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12281-010-0018-6","article-title":"Use of antifungal combination therapy: agents, order, and timing","volume":"4","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B61","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.01556-08","article-title":"Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/2047-783X-16-4-167","article-title":"Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature","volume":"16","year":"2011","journal-title":"Eur J Med Res"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B63","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/ajt.12963","article-title":"Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B64","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","year":"2007","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B65","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B66","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00581-15","article-title":"Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B67","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00277-015-2333-z","article-title":"Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients\u2014an evidence-based approach","volume":"94","year":"2015","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20170317082738_dkx033-B68","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.01423-10","article-title":"Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/suppl_1\/i48\/11021794\/dkx033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T15:33:20Z","timestamp":1719070400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkx033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":68,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2017,3,17]]},"published-print":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx033","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}